To determine Charlson comorbidity Index score and estimate 10 years survival rate in patients with multiple comorbidities.
The Charlson Comorbidity Index was developed in 1987 by Charlson and colleagues to classify comorbid conditions which may influence mortality risk. The Charlson comorbidity index (CCI) is the most widely used comorbidity index used to determine survival rate (1yr and 10yr) in patient with multiple comorbidities. This tool was originally supposed to be used in longitudinal studies A weighted index that takes into account the number and the seriousness of comorbid disease was developed in a cohort of 559 medical patients. The 1-yr mortality rates for the different scores were: "0", 12% (181); "1-2", 26% (225); "3-4", 52% (71); and "≥ 5", 85% (82). The index was tested for its ability to predict risk of death from comorbid disease in the second cohort of 685 patients during a 10-yr follow-up. The percent of patients who died of comorbid disease for the different scores were: "0", 8% (588); "1", 25% (54); "2", 48% (25); " ≥ 3", 59% (18). With each increased level of the comorbidity index, there were stepwise increases in the cumulative mortality attributable to comorbid disease .It contains 19 issues including diabetes with diabetic complications, congestive heart failure, peripheral vascular disease, chronic pulmonary disease, mild and severe liver disease, hemiplegia, renal disease, leukaemia, lymphoma, metastatic tumor, and acquired immunodeficiency syndrome (AIDS), each of which was weighted according to their potential influence on mortality. Since then, CCI has been adapted and verified as applicable and valid for predicting the outcome and risk of death from many comorbid diseases.
References
Charlson ME, Pompei P, Ales KL, MacKenzie CR.
A new method of classifying prognostic comorbidity in
longitudinal studies: development and validation.
J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8. PMID: 3558716.
Charlson ME, Pompei P, Ales KL, MacKenzie CR.
The Charlson Comorbidity Index was developed in 1987 by Charlson and colleagues to classify comorbid conditions which may influence mortality risk. The Charlson comorbidity index (CCI) is the most widely used comorbidity index used to determine survival rate (1yr and 10yr) in patient with multiple comorbidities. This tool was originally supposed to be used in longitudinal studies A weighted index that takes into account the number and the seriousness of comorbid disease was developed in a cohort of 559 medical patients. The 1-yr mortality rates for the different scores were: "0", 12% (181); "1-2", 26% (225); "3-4", 52% (71); and "≥ 5", 85% (82). The index was tested for its ability to predict risk of death from comorbid disease in the second cohort of 685 patients during a 10-yr follow-up. The percent of patients who died of comorbid disease for the different scores were: "0", 8% (588); "1", 25% (54); "2", 48% (25); " ≥ 3", 59% (18). With each increased level of the comorbidity index, there were stepwise increases in the cumulative mortality attributable to comorbid disease .It contains 19 issues including diabetes with diabetic complications, congestive heart failure, peripheral vascular disease, chronic pulmonary disease, mild and severe liver disease, hemiplegia, renal disease, leukaemia, lymphoma, metastatic tumor, and acquired immunodeficiency syndrome (AIDS), each of which was weighted according to their potential influence on mortality. Since then, CCI has been adapted and verified as applicable and valid for predicting the outcome and risk of death from many comorbid diseases.
References
Charlson ME, Pompei P, Ales KL, MacKenzie CR.
A new method of classifying prognostic comorbidity in
longitudinal studies: development and validation.
J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8. PMID: 3558716.
Charlson ME, Pompei P, Ales KL, MacKenzie CR.
© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.